Prosecution Insights
Last updated: April 19, 2026
Application No. 18/024,631

DERIVATISATION OF PEPTIDES AND PROTEINS

Non-Final OA §102
Filed
Mar 03, 2023
Examiner
CHANDRA, GYAN
Art Unit
1674
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Florey Institute Of Neuroscience And Mental Health
OA Round
1 (Non-Final)
71%
Grant Probability
Favorable
1-2
OA Rounds
2y 9m
To Grant
99%
With Interview

Examiner Intelligence

Grants 71% — above average
71%
Career Allow Rate
695 granted / 978 resolved
+11.1% vs TC avg
Strong +28% interview lift
Without
With
+27.5%
Interview Lift
resolved cases with interview
Typical timeline
2y 9m
Avg Prosecution
38 currently pending
Career history
1016
Total Applications
across all art units

Statute-Specific Performance

§101
3.6%
-36.4% vs TC avg
§103
29.5%
-10.5% vs TC avg
§102
19.2%
-20.8% vs TC avg
§112
29.5%
-10.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 978 resolved cases

Office Action

§102
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim 1 is pending and under examination. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 1 is rejected under 35 U.S.C. 102(a)(1) as being anticipated by Hossain et al. (JACS, 2020, 1164-1169, published 12/18/2019). The instantly claimed invention is broadly drawn to a method for glycosylating a peptide or protein, comprising the steps of: a) providing a peptide or protein comprising an amino acid residue comprising an unprotected nucleophilic group; and b) reacting the nucleophilic group with a glycosyl moiety substituted with a leaving group to provide a glycosylated peptide or protein. Hossain et. al. teach that glycosylation is an accepted strategy to improve therapeutic valued of a peptide or protein drug (abstract). They teach inserting a cysteine amino acid to insulin molecule and then attaching a sialic acid sugar to glycosylate the insulin molecule (Figure 1A). Cysteine comprises unprotected nucleophilic group which reacts with glycosyl moiety resulting in glycosylated insulin molecule. Therefore, the instantly claimed invention is implicitly or explicitly anticipated by the prior art. Conclusion Claim 1 is rejected. Any inquiry concerning this communication or earlier communications from the examiner should be directed to GYAN CHANDRA whose telephone number is (571)272-2922. The examiner can normally be reached Mon-Friday 8:30AM-5:00P. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Vanessa Ford can be reached at 571-272-0857. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /GYAN CHANDRA/Primary Examiner, Art Unit 1674
Read full office action

Prosecution Timeline

Mar 03, 2023
Application Filed
Oct 04, 2025
Non-Final Rejection — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12600758
INTERLEUKIN-2 MUTEINS FOR THE EXPANSION OF T-REGULATORY CELLS
2y 5m to grant Granted Apr 14, 2026
Patent 12600771
ANTIBODY FOR BINDING TO INTERLEUKIN 4 RECEPTOR
2y 5m to grant Granted Apr 14, 2026
Patent 12594323
METHODS OF REDUCING NEUROINFLAMMATION
2y 5m to grant Granted Apr 07, 2026
Patent 12589142
HLA TUMOR ANTIGEN PEPTIDES OF CLASS I AND II FOR TREATING MAMMARY/BREAST CARCINOMAS
2y 5m to grant Granted Mar 31, 2026
Patent 12576136
Insulin Derivative
2y 5m to grant Granted Mar 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
71%
Grant Probability
99%
With Interview (+27.5%)
2y 9m
Median Time to Grant
Low
PTA Risk
Based on 978 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month